Targeted Assessment of the EGFR Status as Reflex Testing in Treatment-Naive Non-Squamous Cell Lung Carcinoma Patients: A Single Laboratory Experience (LPCE, Nice, France)

Cancers

Jacques Boutros¹  Michel Poudenx²  Charles Marquette²  Jonathan Benzaquen²  Christelle Bonnetaud³  Jean-Marc Félix³  Virginie Tanga³  Virginie Lespinet⁴  Véronique Hofman⁴  Sandra Lassalle⁴  Simon Heeke⁴  Katia Zahaf⁴  Elodie Long⁴  Paul Hofman⁴  Olivier Bordone⁴  Elisabeth Lantéri⁴  Salomé Lalvée⁴  Marius Ilie⁴ 

[1] Department of Pneumology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, France;FHU OncoAge, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, France;Hospital-Related Biobank (BB-0033-00025), Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, France;Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, University Côte d’Azur, 30 avenue de la voie romaine, 06000 Nice, France;

关键词: lung cancer;    EGFR;    targeted sequencing;    next generation sequencing;   

DOI  :  10.3390/cancers12040955

来源: DOAJ

【 摘 要 】

Background: Assessment of actionable EGFR mutations is mandatory for treatment-naïve advanced or metastatic non-squamous lung carcinoma (NSLC), but the results need to be obtained in less than 10 working days. For rapid EGFR testing, an EGFR-specific polymerase chain reaction (PCR) assay is an alternative and simple approach compared to next generation sequencing (NGS). Here, we describe how a rapid EGFR-specific PCR assay can be implemented in a single laboratory center (LPCE, Nice, France) as reflex testing in treatment-naïve NSLC. Methods: A total of 901 biopsies from NSLC with more than 10% of tumor cells were prospectively and consecutively evaluated for EGFR mutation status between November 2017 and December 2019 using the Idylla system (Biocartis NV, Mechelen, Belgium). NGS was performed for nonsmokers with NSLC wild type for EGFR, ALK, ROS1, and BRAF and with less than 50% PD-L1 positive cells using the Hotspot panel (Thermo Fisher Scientific, Waltham, MA, USA). Results: Results were obtained from 889/901 (97%) biopsies with detection of EGFR mutations in 114/889 (13%) cases using the Idylla system. Among the 562 EGFR wild type tumors identified with Idylla, NGS detected one actionable and one nonactionable EGFR mutation. Conclusions: Rapid and targeted assessment of EGFR mutations in treatment-naïve NSLC can be implemented in routine clinical practice. However, it is mandatory to integrate this approach into a molecular algorithm that allows evaluation of potentially actionable genomic alterations other than EGFR mutations.

【 授权许可】

Unknown